Letter to the Editor: Streptokinase induced Purpura like lesions by Gupta, S et al.
African Journal of Health Sciences, Volume 20, Number 1-2 January-March 2012 
 
1 
Letter to the Editor. 
Streptokinase induced Purpura like lesions. 
 
 
Gupta S12, Thomas M3, DNB, Pandey P4, Aggarwal M5. 
 
1Department Of Medicine MM Institute of Medical Sciences and Research, Mullana  Ambala- India. 
2Department of Dermatology and STI, MM Institute of Medical Sciences and Research, Mullana  
Ambala- India. 
3Consultant Dermatologist, Bangalore India.  
4Department of Pathology, MM Institute of Medical Sciences and Research, Mullana  Ambala- India. 
5Consultant Physician, Aggarwal Heart Hospital Ambala City     
  
 
 Address for Correspondence: Dr. Sanjeev Gupta, H.No. B-2, Near Shiv Mandir, MM Medical 








We present a case of Streptokinase induced 
vasculitis presenting as purpuric lesions 
immediately after streptokinase therapy. 
Streptokinase is a frequently used 
thrombolytic agent in clinical practice. The 
common unwanted effects include 
hemorrhage, fever, and an immediate allergic 
reaction .  Serum sickness 1,2  and crescentic 
glomerulo-nephritis have also been described 
after streptokinase treatment. In each case the 
patient had a purpuric rash . A further two 
papers describe non-specific rashes caused by 
streptokinase . We report the development of 
small vessel vasculitis in a patient treated with 
streptokinase for  acute myocardial infarction.  
Eighty year old male was admitted with  
myocardial infarction. He  was  known 
hypertensive and was on treatment with  beta 
blockers, asprin  and statins. His pre 
thrombolysis bleeding parameters were within 
normal limits and was thrombolysed  with  
streptokinase 150000 IU. Just after 
thrombolysis he developed multiple purpuric 
lesions involving the entire body, 
predominantly distributed on the extensor 
aspects of the extremities associated with 




Fig1: Multiple purpuric lesions on 
extremeties. 
 
There was no associated arthralgias,  fever and 
joint pains. His blood counts, urine and stool 
analysis, liver and renal function tests were 
within normal limits. He had not been started 
on any oral or injectable anticoagulants or 
other medications and had no history of any 
infections in the recent past. Differential 
diagnosis of drug induced purpura or 
hypersensitivity vasculitis were considered. 
Routine investigations were within normal 
limits. A skin biopsy from a lesion on the left 
leg revealed hyperkeratosis of stratum 
corneum, below which there was dense 
mononuclear infiltrate in  both intravascular 
and perivascular region. Some areas showed 
extravasation of red blood cells (RBC), edema, 
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Fig 2.  (H&E 200 x) Photomicrograph 
showing numerous blod vessels infiltrated 
with fragmented neutrophils, marked 
derma edema and dense neutrophilic 
infiltrate in stroma. 
 
 Based on the clinical and histological 
findings, a diagnosis of streptokoinase induced 
vasculitis was made. The lesions did not 
aggravate further and started resolving with  
conservative treatment.  
 
Streptokinase is a non-enzymatic protein (47 
kD) produced by group C streptococci .  The 
reported frequency of allergic reactions to the 
drug varies between 1-7% and 18% 3 of which 
the majority is mild and self-limiting, taking 
the form of acute immediate-type 
hypersensitivity reactions including urticaria, 
angioedema, bronchospasm and anaphylaxis, 
and delayed cutaneous lymphocytic reactions 
have been reported 4. Although 
leucocytoclastic vasculitis and serum sickness 
have been reported after streptokinase 
treatment, Streptokinase induced vasculitis is a 
rare entity. The pathogenesis is uncertain but 
may be a direct toxic reaction to the initial 
high dose of the drug damaging the capillaries 
of the dermo-vascular loop with local 
deposition of immune complexes 5. There are 
close antigenic similarities between group A 
streptococci, which include the common 
human pathogen S.pyogenes, and group C 
streptococci from which streptokinase 
isproduced. Pre-sensitized by a previous 
streptococcal infection may result in the 
formation of antibodies cross-reactive with 
streptokinase resulting in rapid and vigorous 
secondary immune response when that antigen 
was administered exogenously resulting in 
immune complex deposition . Skin lesions in 
this rare reaction to anticoagulant drugs is 
known to become dramatically evident 
between the third and tenth day of therapy. In 
our case the lesions developed immediately on 
the day of streptokinase therapy. Such early 
onset of lesions has not been described so far. 
Awareness of this complication  induced by 
streptokinase must be known to cardiologists 
as well to dermatologists. The distinction must 
be drawn  between the long term benefit of 
myocardial salvage and the small risk of a 
transient allergic reaction that seems on 
present evidence to be benign.  
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